Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Causes & Control
Published in: Cancer Causes & Control 12/2017

01-12-2017 | Original paper

Menstrual cycle characteristics and steroid hormone, prolactin, and growth factor levels in premenopausal women

Authors: Leslie V. Farland, Fan Mu, A. Heather Eliassen, Susan E. Hankinson, Shelley S. Tworoger, Robert L. Barbieri, Mitch Dowsett, Michael N. Pollak, Stacey A. Missmer

Published in: Cancer Causes & Control | Issue 12/2017

Login to get access

Abstract

Purpose

Menstrual cycle characteristics are markers of endocrine milieu. However, associations between age at menarche and adulthood sex steroid hormone levels have been inconsistent, and data on menstrual characteristics and non-sex steroid hormones are sparse.

Methods

We assessed the relations of menstrual characteristics with premenopausal plasma sex steroid hormones, sex hormone binding globulin (SHBG), prolactin, and growth factors among 2,745 premenopausal women (age 32–52) from the Nurses’ Health Study II. Geometric means and tests for trend were calculated using multivariable general linear models.

Results

Early age at menarche was associated with higher premenopausal early-follicular free estradiol (percent difference < 12 vs. > 13 years = 11%), early-follicular estrone (7%), luteal estrone (7%), and free testosterone (8%) (all p trend < 0.05). Short menstrual cycle length at age 18–22 was associated with higher early-follicular total (< 26 vs. > 39 days = 18%) and free estradiol (16%), early-follicular estrone (9%), SHBG (7%), lower luteal free estradiol (− 14%), total (− 6%), and free testosterone (− 15%) (all p trend < 0.05). Short adult menstrual length was associated with higher early-follicular total estradiol (< 26 vs. > 31 days = 14%), SHBG (10%), lower luteal estrone (− 8%), progesterone (− 9%), total (− 11%) and free testosterone (− 25%), and androstenedione (− 14%) (all p trend < 0.05). Irregularity of menses at 18–22 was associated with lower early-follicular total (irregular vs. very regular = − 14%) and free estradiol (− 14%), and early-follicular estrone (− 8%) (All p trend < 0.05). Irregularity of adult menstrual cycle was associated with lower luteal total estradiol (irregular vs. very regular = − 8%), SHBG (− 3%), higher total (8%), and free testosterone (11%) (all p trend < 0.05).

Conclusions

Early-life and adulthood menstrual characteristics are moderately associated with mid-to-late reproductive year’s hormone concentrations. These relations of menstrual characteristics with endogenous hormone levels could partially account for associations between menstrual characteristics and reproductive cancers or other chronic diseases.
Appendix
Available only for authorised users
Literature
1.
Rockhill B, Moorman PG, Newman B (1998) Age at menarche, time to regular cycling, and breast cancer (North Carolina, United States). Cancer Causes Control 9(4):447–453CrossRefPubMed
2.
Missmer SA, Hankinson SE, Spiegelman D, Barbieri RL, Malspeis S, Willett WC et al (2004) Reproductive history and endometriosis among premenopausal women. Obstet Gynecol 104(5 Pt 1):965–974CrossRefPubMed
3.
Lakshman R, Forouhi NG, Sharp SJ, Luben R, Bingham SA, Khaw KT et al (2009) Early age at menarche associated with cardiovascular disease and mortality. J Clin Endocrinol Metab 94(12):4953–4960CrossRefPubMed
4.
Gong TT, Wu QJ, Vogtmann E, Lin B, Wang YL (2013) Age at menarche and risk of ovarian cancer: a meta-analysis of epidemiological studies. Int J Cancer 132(12):2894–2900CrossRefPubMed
5.
MacMahon B, Trichopoulos D, Brown J, Andersen AP, Cole P, deWaard F et al (1982) Age at menarche, urine estrogens and breast cancer risk. Int J Cancer 30(4):427–431CrossRefPubMed
6.
Apter D, Reinila M, Vihko R (1989) Some endocrine characteristics of early menarche, a risk factor for breast cancer, are preserved into adulthood. Int J Cancer 44(5):783–787CrossRefPubMed
7.
Bernstein L, Pike MC, Ross RK, Henderson BE (1991) Age at menarche and estrogen concentrations of adult women. Cancer Causes Control 2(4):221–225CrossRefPubMed
8.
9.
Verkasalo PK, Thomas HV, Appleby PN, Davey GK, Key TJ (2001) Circulating levels of sex hormones and their relation to risk factors for breast cancer: a cross-sectional study in 1092 pre- and postmenopausal women (United Kingdom). Cancer Causes Control 12(1):47–59CrossRefPubMed
10.
Tworoger SS, Sluss P, Hankinson SE (2006) Association between plasma prolactin concentrations and risk of breast cancer among predominately premenopausal women. Cancer Res 66(4):2476–2482CrossRefPubMed
11.
Missmer SA, Spiegelman D, Bertone-Johnson ER, Barbieri RL, Pollak MN, Hankinson SE (2006) Reproducibility of plasma steroid hormones, prolactin, and insulin-like growth factor levels among premenopausal women over a 2- to 3-year period. Cancer Epidemiol Biomark Prev 15(5):972–978CrossRef
12.
Stunkard AJ, Sorensen T, Schulsinger F (1983) Use of the Danish adoption register for the study of obesity and thinness. Res Publ 60:115–120
13.
Rosner B (1983) Percentage points for a generalized ESD many-outlier procedure. Technometrics 25:165–172CrossRef
14.
Rosner B, Cook N, Portman R, Daniels S, Falkner B (2008) Determination of blood pressure percentiles in normal-weight children: some methodological issues. Am J Epidemiol 167(6):653–666CrossRefPubMed
15.
Eliassen AH, Missmer SA, Tworoger SS, Spiegelman D, Barbieri RL, Dowsett M et al (2006) Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women. J Natl Cancer Inst 98(19):1406–1415CrossRefPubMed
16.
Hosmer DW, Lemeshow S (1989) Applied logistic regression. Wiley, New York
17.
Yen S.S.C., Jaffe RB (1991) Reproductive endocrinology, 3rd edn. W.B. Saunders Company, Philadelphia
18.
Apter D, Bolton NJ, Hammond GL, Vihko R (1984) Serum sex hormone-binding globulin during puberty in girls and in different types of adolescent menstrual cycles. Acta Endocrinol 107(3):413–419PubMed
19.
Westhoff C, Gentile G, Lee J, Zacur H, Helbig D (1996) Predictors of ovarian steroid secretion in reproductive-age women. Am J Epidemiol 144(4):381–388CrossRefPubMed
20.
Moore JW, Key TJ, Wang DY, Bulbrook RD, Hayward JL, Takatani O (1991) Blood concentrations of estradiol and sex hormone-binding globulin in relation to age at menarche in premenopausal British and Japanese women. Breast Cancer Res Treat 18(Suppl 1):S47–S50
21.
Windham GC, Elkin E, Fenster L, Waller K, Anderson M, Mitchell PR et al (2002) Ovarian hormones in premenopausal women: variation by demographic, reproductive and menstrual cycle characteristics. Epidemiology 13(6):675–684CrossRefPubMed
22.
Apter D, Vihko R (1985) Premenarcheal endocrine changes in relation to age at menarche. Clin Endocrinol (Oxf) 22(6):753–760CrossRef
23.
Feigelson HS, Shames LS, Pike MC, Coetzee GA, Stanczyk FZ, Henderson BE (1998) Cytochrome P450c17alpha gene (CYP17) polymorphism is associated with serum estrogen and progesterone concentrations. Cancer Res 58(4):585–587PubMed
24.
Garcia-Closas M, Herbstman J, Schiffman M, Glass A, Dorgan JF (2002) Relationship between serum hormone concentrations, reproductive history, alcohol consumption and genetic polymorphisms in pre-menopausal women. Int J Cancer 102(2):172–178CrossRefPubMed
25.
Lai J, Vesprini D, Chu W, Jernstrom H, Narod SA (2001) CYP gene polymorphisms and early menarche. Mol Genet Metab 74(4):449–457CrossRefPubMed
26.
Ambrosone CB, Moysich KB, Furberg H, Freudenheim JL, Bowman ED, Ahmed S et al (2003) CYP17 genetic polymorphism, breast cancer, and breast cancer risk factors. Breast Cancer Res 5(2):R45–R51CrossRef
27.
Wronka I (2010) Association between BMI and age at menarche in girls from different socio-economic groups. Anthropologischer Anzeiger 68(1):43–52CrossRef
28.
Dorgan JF, Reichman ME, Judd JT, Brown C, Longcope C, Schatzkin A et al (1995) Relationships of age and reproductive characteristics with plasma estrogens and androgens in premenopausal women. Cancer Epidemiol Biomark Prev 4(4):381–386
29.
Moore JW, Key TJ, Clark GM, Hoare SA, Allen DS, Wang DY (1987) Sex-hormone-binding globulin and breast cancer risk. Anticancer Res 7(5B):1039–1047PubMed
30.
Pierce MB, Leon DA (2005) Age at menarche and adult BMI in the Aberdeen children of the 1950s cohort study. Am J Clin Nutr 82(4):733–739PubMed
31.
Tchernof A, Despres JP (2000) Sex steroid hormones, sex hormone-binding globulin, and obesity in men and women. Horm Metab Res 32(11–12):526–536CrossRefPubMed
32.
Tchernof A, Toth MJ, Poehlman ET (1999) Sex hormone-binding globulin levels in middle-aged premenopausal women. Associations with visceral obesity and metabolic profile. Diabetes Care 22(11):1875–1881CrossRefPubMed
33.
Pasquali R, Vicennati V, Bertazzo D, Casimirri F, Pascal G, Tortelli O et al (1997) Determinants of sex hormone-binding globulin blood concentrations in premenopausal and postmenopausal women with different estrogen status. Virgilio-Menopause-Health Group Metab 46(1):5–9
34.
Mumford SL, Steiner AZ, Pollack AZ, Perkins NJ, Filiberto AC, Albert PS et al (2012) The utility of menstrual cycle length as an indicator of cumulative hormonal exposure. J Clin Endocrinol Metab 97(10):E1871-9CrossRefPubMed
35.
Fortner RT, Hankinson SE, Schairer C, Xu X, Ziegler RG, Eliassen AH (2012) Association between reproductive factors and urinary estrogens and estrogen metabolites in premenopausal women. Cancer Epidemiol Biomark Prev 21(6):959–968CrossRef
36.
Waller K, Swan SH, Windham GC, Fenster L, Elkin EP, Lasley BL (1998) Use of urine biomarkers to evaluate menstrual function in healthy premenopausal women. Am J Epidemiol 147(11):1071–1080CrossRefPubMed
37.
Speroff LAFM (2005) Clinical gynecologic endocrinology and infertility. Lippincott Williams & Wilkin, Philadelphia, pp 223–224
38.
Harlow SD, Baird DD, Weinberg CR, Wilcox AJ (2000) Urinary oestrogen patterns in long follicular phases. Hum Reprod 15(1):11–16CrossRefPubMed
39.
Wei S, Jones G, Thomson R, Otahal P, Dwyer T, Venn A (2010) Menstrual irregularity and bone mass in premenopausal women: cross-sectional associations with testosterone and SHBG. BMC Musculoskelet Disord 11:288CrossRefPubMedPubMedCentral
40.
Van Anders SM, Watson NV (2006) Menstrual cycle irregularities are associated with testosterone levels in healthy premenopausal women. Am J Hum Biol 18(6):841–844CrossRefPubMed
41.
Speroff LAFM (2005) Clinical gynecologic endocrinology and infertility. Lippincott Williams & Wilkin, Philadelphia, p 465
42.
Lukanova A, Toniolo P, Akhmedkhanov A, Hunt K, Rinaldi S, Zeleniuch-Jacquotte A et al (2001) A cross-sectional study of IGF-I determinants in women. Eur J Cancer Prev 10(5):443–452CrossRefPubMed
43.
Johansson H, Baglietto L, Guerrieri-Gonzaga A, Bonanni B, Mariette F, Macis D et al (2004) Factors associated with circulating levels of insulin-like growth factor-I and insulin-like growth factor binding protein-3 in 740 women at risk for breast cancer. Breast Cancer Res Treat 88(1):63–73CrossRefPubMed
44.
Key TJ, Appleby PN, Reeves GK, Roddam AW (2010) Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies. Lancet Oncol 11(6):530–542CrossRefPubMed
Metadata
Title
Menstrual cycle characteristics and steroid hormone, prolactin, and growth factor levels in premenopausal women
Authors
Leslie V. Farland
Fan Mu
A. Heather Eliassen
Susan E. Hankinson
Shelley S. Tworoger
Robert L. Barbieri
Mitch Dowsett
Michael N. Pollak
Stacey A. Missmer
Publication date
01-12-2017
Publisher
Springer International Publishing
Published in
Cancer Causes & Control / Issue 12/2017
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-017-0971-2

Other articles of this Issue 12/2017

Cancer Causes & Control 12/2017 Go to the issue

Original paper

Economic and disease burden of breast cancer associated with suboptimal breastfeeding practices in Mexico

Original paper

Alcohol consumption and mammographic density in the Danish Diet, Cancer and Health cohort

Original paper

The relationship between physical activity, obesity, and lung cancer risk by smoking status in a large prospective cohort of US adults

Original paper

Treatment and survival disparities by ethnicity in New Zealand women with stage I–III breast cancer tumour subtypes

Original paper

Sedentary time and postmenopausal breast cancer incidence

Original paper

Endogenous sex hormone exposure and repetitive element DNA methylation in healthy postmenopausal women
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits